Is the price fair?
What ARGX's price assumes
argenx SE trades at 53.5× earnings against 32.4× for the median Biotechnology name, more expensive than its own group.
53.5
Trailing P/E · Biotechnology median 32.4 · 1.65× the median: the market pays up for this one
- Price / sales
- 8.21
Price / sales · as of 2025-Q4
- Free cash flow yield
- 1.2%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +24%
Growth the price implies · The price pays for +24% free cash flow growth a year for a decade; revenue has grown +112% a year over the last three.
Details›
- Price / book2025-Q4
- 7.11
- Healthcare median P/E362 names
- 31.5
- Biotechnology median P/E158 names
- 32.4
- Free cash flow, trailing twelve months
- $679M
- Market capitalisation
- $54.9B
- 3-year revenue growth
- +112%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.